Hong Kong, Shanghai - HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) today announces that results from ESLIM-01, HUTCHMED s Phase III trial of sovleplenib, in adult patients with primary immune thrombocytopenia in China, were published in The Lancet Haematology.

Additional details and subgroup results of the study were also presented on June 14 at the European Hematology Association ( EHA ) 2024 Hybrid Congress as an oral and two poster presentations.

Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase ( Syk ) for the treatment of hematological malignancies and immune diseases. Syk is a component in Fc receptor ( FcR ) and B-cell receptor signaling pathway. ITP is a complex autoimmune bleeding disorder, leading to a reduced platelet level in the peripheral blood. ITP can also impact on patients quality of life due to fatigue, restrictions on activities and anxiety. The ESLIM-01 trial results published by The Lancet Haematology suggest that sovleplenib could be a potential treatment option for patients with ITP who received at least one prior therapy.

ESLIM-01 is a 2:1 randomized, double-blind, Phase III study conducted in 188 adult patients with primary ITP who had received at least one previous anti-ITP treatment (NCT05029635). The study demonstrated a clinically meaningful early and sustained durable platelet response in patients with primary ITP, with a tolerable safety profile and improvement in quality of life. The primary endpoint was met, with durable response rate of 48.4% (61/126) with sovleplenib compared to zero with placebo (p

(C) 2024 Electronic News Publishing, source ENP Newswire